AP NEWS

U.S. Major Depressive Disorder (MDD) Market Analysis & Outlook 2018-2022 - Players Featured are Pfizer, AstraZeneca, Eli Lilly & Company, and Lundbeck - ResearchAndMarkets.com

August 21, 2018

DUBLIN--(BUSINESS WIRE)--Aug 21, 2018--The “U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2022)” report has been added to ResearchAndMarkets.com’s offering.

The report provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. market.

The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.

MDD is the most common mental disorder in the U.S. Approximately 16 million American adults suffer from the major depressive disorder and about one-third of the MDD patient remain untreated. The number of treated patients is projected to rise on account of better medical access and rising awareness regarding depression.

There are few potential drugs in development that are being developed with improved efficacy and safety for the treatment of MDD and are expected to contribute significantly to the market growth in the U.S.

Market Dynamics

Growth Drivers

Growing Aging Population Rising Female Population Increasing Spending on Prescription Drugs Increasing Prevalence of Depression Growing Mental Health Expenditure Unmet Need

Key Trends & Developments

Increasing Awareness for Depression Direct to Customer Advertising Rapid Acting Drugs In Development Rising Number of Mental Health Programs

Challenges

Stringent Drug Regulations Patent Expiry of Drugs Complications and Side Effects associated with Anti-depressants Availability of Other Therapies such as Meditation and Psychotherapy

Key Topics Covered

1. Market Overview

2. The U.S. MDD Market

3. Market Dynamics

4. Competitive Landscape

5. Company Profiles

Pfizer Inc. AstraZeneca Eli Lilly & Company Lundbeck

For more information about this report visit https://www.researchandmarkets.com/research/3hp8cs/u_s_major?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180821005590/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Disorders Drugs

KEYWORD: UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/21/2018 01:43 PM/DISC: 08/21/2018 01:43 PM

http://www.businesswire.com/news/home/20180821005590/en

AP RADIO
Update hourly